# iShares NASDAQ US Biotechnology UCITS ETF (BTEK) **Page:** https://fundology.uk/fund/btek · ISIN IE00BYXG2H39 ## At a glance > Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise. As of 13/11/2026, BTEK (iShares NASDAQ US Biotechnology UCITS ETF, ISIN IE00BYXG2H39) closed at £7.92 on the London Stock Exchange. Its ongoing charge is 0.35% a year (about £35 on £10,000). Over the five years to 13/11/2026 its total return was +57.1%, or +22.6% after UK CPIH inflation. ## Summary iShares NASDAQ US Biotechnology UCITS ETF is an exchange-traded fund (ETF) from iShares, launched in 2017. It tracks the NASDAQ / Biotechnology. You buy and sell it through a share-dealing account or platform during stock-market hours, like a share. Its ongoing charge is 0.35% a year — about £35 a year on every £10,000 invested, taken from the fund's value rather than billed to you. Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you. Latest close: **£7.92** (13/11/2026). ## Key facts | Fact | Value | |---|---| | Ticker (LSE) | BTEK | | ISIN | IE00BYXG2H39 | | Also listed as | BTEC (London Stock Exchange, US dollars), 2B70 (Xetra, euros) | | Category | Healthcare | | Type | ETF | | Provider | iShares | | Tracks | NASDAQ / Biotechnology | | Income | Accumulating | | Ongoing charge | 0.35% a year (£35 per £10,000) | | Fund size | £1.0bn | | Launched | 2017 | | Domicile | Ireland | | UK reporting fund status | Yes — on HMRC’s list of reporting funds (list of 02/11/2026); reporting fund since 19/10/2017 | ## Past returns (periods to 13/11/2026) After the fund's ongoing charges. "Income reinvested" is total return; "price only" leaves out income paid out. Real returns are after UK CPIH inflation. | Window | Return | After CPIH inflation | Measured as | |---|---|---|---| | 1 year | +33.24% | +28.52% | income reinvested | | 3 years | +86.37% | +68.38% | income reinvested | | 5 years | +57.13% | +22.65% | income reinvested | Returns: as reported (delayed data). Inflation: UK CPIH, latest month published. ## Calendar-year returns Calendar-year returns of iShares NASDAQ US Biotechnology UCITS ETF in pounds (price, with income reinvested in the fund): 2022 −1.6%, 2023 +0.3%, 2024 +2.1%, 2025 +20.4%; 2026 to 13/11/2026 +28.8%. Returns of iShares NASDAQ US Biotechnology UCITS ETF in pounds (price, with income reinvested in the fund) over the 12 months to 30/09/2026: +43.4%; to 30/09/2025: +6.0%; to 30/09/2024: +10.2%; to 30/09/2023: −5.4%; to 30/09/2022: −5.3%. | Year | Return | After CPIH inflation | Measured as | |---|---|---|---| | 2022 | -1.6% | -9.9% | Price | | 2023 | +0.3% | -3.7% | Price | | 2024 | +2.1% | -1.4% | Price | | 2025 | +20.4% | +16.3% | Price | | 2026 to 13/11/2026 | +28.8% | +24.7% | Price | ## Risk metrics | Window | Volatility | Max drawdown | |---|---|---| | 1 year | 19.66% | -6.11% | | 3 years | 19.28% | -23.44% | | 5 years | 19.02% | -23.44% | ## Largest fall Volatility of iShares NASDAQ US Biotechnology UCITS ETF in pounds, annualised from weekly returns to 13/11/2026: 19.7% over 1 year, 19.3% over 3 years, 19.0% over 5 years. Largest fall in the price of iShares NASDAQ US Biotechnology UCITS ETF since November 2021, in pounds: −23.4% from 26/07/2024 to 11/04/2025. The lowest 12-month return of iShares NASDAQ US Biotechnology UCITS ETF in pounds (price, with income reinvested in the fund) since January 2021 was −21.7% (12 months to 18/02/2022); the highest was +60.6% (12 months to 03/07/2026). On 13/11/2026 the price of iShares NASDAQ US Biotechnology UCITS ETF was 0.7% below its highest weekly close since November 2021 (30/10/2026), in pounds. ## Charges compared with similar funds Ongoing charge of iShares NASDAQ US Biotechnology UCITS ETF 0.35% a year. Compared on 14/11/2026, 11 of the 28 other healthcare funds charge more, 3 the same and 14 less (share classes counted once). ## Funds tracking the same index 3 funds track NASDAQ / Biotechnology, this one included and share classes counted once; their ongoing charges range from 0.35% to 0.40% a year (13/11/2026). | Fund | Ongoing charge | 1 year | 3 years | 5 years | |---|---|---|---|---| | Invesco NASDAQ Biotech UCITS ETF | 0.40% | +33.3% | +86.5% | +57.3% | | iShares NASDAQ US Biotechnology UCITS ETF (this fund) | 0.35% | +33.2% | +86.4% | +57.1% | | iShares NASDAQ US Biotechnology UCITS ETF Dist | 0.35% | +34.0% | +86.5% | +57.5% | Returns are as reported, in pounds, income reinvested unless marked "(price)". ## Charges & eligibility - Ongoing charges figure (OCF): **0.35%** per year - Stocks and shares ISA eligible: usually (check with your platform) - SIPP eligible: usually (check with your provider) - ISA and SIPP mean the kind of product usually qualifies under HMRC rules. We do not check each platform’s list — each provider decides which funds it offers. Crypto ETNs have not qualified for a stocks and shares ISA since 06/04/2026, and overseas funds that are not UK-recognised UCITS, such as Swiss ETFs, do not usually qualify. ## What it holds As of 06/11/2026, BTEK holds 250 positions, according to its published holdings. The largest is Gilead Sciences at 8.96% of the fund; the ten largest make up 48.5%. ### Top holdings Largest positions (as of 06/11/2026), as a percentage of the whole fund: | # | Holding | Ticker | Weight | |---|---|---|---| | 1 | Gilead Sciences | [GILD](https://fundology.uk/stock/GILD) | 8.96% | | 2 | Amgen | [AMGN](https://fundology.uk/stock/AMGN) | 8.40% | | 3 | Vertex Pharmaceuticals | [VRTX](https://fundology.uk/stock/VRTX) | 7.88% | | 4 | Moderna | [MRNA](https://fundology.uk/stock/MRNA) | 6.52% | | 5 | Regeneron Pharmaceuticals | [REGN](https://fundology.uk/stock/REGN) | 5.88% | | 6 | Revolution Medicines | [RVMD](https://fundology.uk/stock/RVMD) | 2.65% | | 7 | Biogen | [BIIB](https://fundology.uk/stock/BIIB) | 2.36% | | 8 | Illumina | [ILMN](https://fundology.uk/stock/ILMN) | 2.07% | | 9 | Royalty Pharma · Class A | [RPRX](https://fundology.uk/stock/RPRX) | 1.93% | | 10 | Roivant Sciences | [ROIV](https://fundology.uk/stock/ROIV) | 1.81% | ## Where it invests Shares of the whole fund. Bonds, cash and positions without a classification are shown as they come, not guessed. ### By sector As published for the fund, as of 06/11/2026. | Sector | Weight | |---|---| | Health Care | 99.9% | | Cash and derivatives | 0.1% | ### By type of asset Added up from the fund’s published holdings, as of 06/11/2026. | Type of asset | Weight | |---|---| | Equity | 99.9% | | Cash and money market | 0.1% | The 244 holdings on record (of 250 reported): https://fundology.uk/fund/btek/holdings ## Questions people ask **What is the ongoing charge of BTEK?** The ongoing charge of BTEK is 0.35% a year — about £35 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of iShares NASDAQ US Biotechnology UCITS ETF 0.35% a year. Compared on 14/11/2026, 11 of the 28 other healthcare funds charge more, 3 the same and 14 less (share classes counted once). **What does BTEK track?** BTEK tracks the NASDAQ / Biotechnology. **Is BTEK accumulating or distributing?** BTEK is accumulating: income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you. **What is the ISIN of BTEK?** The ISIN of BTEK is IE00BYXG2H39. An ISIN identifies one exact share class of a fund; BTEK is its ticker on the London Stock Exchange. The same share class is also listed as BTEC (London Stock Exchange, US dollars) and 2B70 (Xetra, euros). **What does BTEK hold?** As of 06/11/2026, BTEK holds 250 positions, according to its published holdings. The largest is Gilead Sciences at 8.96% of the fund; the ten largest make up 48.5%. Its ten largest holdings are Gilead Sciences (8.96%), Amgen (8.40%), Vertex Pharmaceuticals (7.88%), Moderna (6.52%), Regeneron Pharmaceuticals (5.88%), Revolution Medicines (2.65%), Biogen (2.36%), Illumina (2.07%), Royalty Pharma · Class A (1.93%) and Roivant Sciences (1.81%). **What were BTEK’s returns in each of the last five years?** Calendar-year returns of BTEK in pounds (price, with income reinvested in the fund): 2022 −1.6%, 2023 +0.3%, 2024 +2.1%, 2025 +20.4%; 2026 to 13/11/2026 +28.8%. Past performance is not a guide to future returns. **How has BTEK done after inflation?** Over the five years to 13/11/2026 BTEK’s total return was +57.1%, or +22.6% after UK CPIH inflation. Past performance is not a guide to future returns. ## Fund documents - [Fund page at iShares](https://www.ishares.com/uk/individual/en/products/291450/ishares-nasdaq-us-biotechnology-ucits-etf) - [Key investor information document (KIID)](https://www.ishares.com/gls-download/literature/kiid/ucits_kiid-ishares-nasdaq-us-biotechnology-ucits-etf-gb-ie00byxg2h39-en.pdf) - [Factsheet](https://www.ishares.com/gls-download/literature/fact-sheet/btec-ishares-nasdaq-us-biotechnology-ucits-etf-fund-fact-sheet-en-gb.pdf) - Links checked 12/10/2026. --- We show information. We are not financial advisers, not authorised by the FCA, and never recommend specific investments. Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.